LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, LDL-cholesterol lowering, third-generation PCSK9 inhibitor, today announced that David Cory, CEO, and Evan Stein, MD, PhD, COO / CSO, will participate in a virtual fireside chat at the Piper Sandler Virtual Cardio Day on April 10, 2024 at 10:30 AM ET. Participants will include leadership from presenting companies and highlights from presentations at t